STOCK TITAN

MapLight Therapeutics (MPLT) 10-K Filings

MPLT NASDAQ

Here are the 10-K annual reports from MapLight Therapeutics, Inc. (MPLT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.

Rhea-AI Summary

MapLight Therapeutics details its clinical-stage CNS drug pipeline and discovery platform focused on debilitating brain disorders. The company’s lead candidate, ML-007C-MA, is an M1/M4 muscarinic agonist–antagonist combo in Phase 2 trials for schizophrenia (ZEPHYR) and Alzheimer’s disease psychosis (VISTA), with FDA Fast Track for hallucinations and delusions in ADP.

ML-007C-MA aims to match central efficacy with reduced peripheral side effects, supported by four Phase 1 studies in 270 participants. A second program, ML-004, repurposes zolmitriptan in an IR/ER tablet for autism spectrum disorder, now in a Phase 2 IRIS trial targeting social communication deficits and irritability.

The pipeline also includes three preclinical programs (ML-009, ML-055, ML-021) built on a circuit-based neuroscience platform using optogenetics and advanced transcriptomics. As of December 31, 2025, MapLight reports a broad patent estate covering its clinical and preclinical assets and retains global rights to all programs.